ArticleGene therapy2000
Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis.
Article in Gene therapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 92 citations in OpenAlex.
- Review
- Peripheral T-cell responses of EphB2- and EphB3-deficient mice in a model of collagen-induced arthritis.Cellular and molecular life sciences : CMLS · 2024Article
- Treatment of Rheumatoid Arthritis with Gene Therapy Applications: Biosafety and Bioethical Considerations.Biotech (Basel (Switzerland)) · 2021Article
- Adenovirus-associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A.Research and practice in thrombosis and haemostasis · 2019Article
- Arthritis models: usefulness and interpretation.Seminars in immunopathology · 2017Review
- Apolipoprotein A-V gene therapy for disease prevention / treatment: a critical analysis.Journal of biomedical research · 2016Review
- Prediction of adeno-associated virus neutralizing antibody activity for clinical application.Gene therapy · 2015Article
- Intra-articular delivery of anti-Hif-2α siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice.Gene therapy · 2015Article
- Super-resolution imaging of nuclear import of adeno-associated virus in live cells.Molecular therapy. Methods & clinical development · 2015Article
- Targeting Atp6v1c1 Prevents Inflammation and Bone Erosion Caused by Periodontitis and Reveals Its Critical Function in Osteoimmunology.PloS one · 2015Article
- Molecular and cell-based therapies for muscle degenerations: a road under construction.Frontiers in physiology · 2014Review
- Inhibiting periapical lesions through AAV-RNAi silencing of cathepsin K.Journal of dental research · 2013Article
- Article
- AAV2-mediated combined subretinal delivery of IFN-α and IL-4 reduces the severity of experimental autoimmune uveoretinitis.PloS one · 2012Article
- Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment.Immunology · 2010Article
- Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus.The journal of gene medicine · 2009Article
- Perspectives on the use of gene therapy for chronic joint diseases.Current gene therapy · 2008Review
- Gene therapy for arthritis.Modern rheumatology · 2008Review
- Treatment of human disease by adeno-associated viral gene transfer.Human genetics · 2006Review
- AAV hybrid serotypes: improved vectors for gene delivery.Current gene therapy · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunomodulation of autoimmune inflammatory diseases like rheumatoid arthritis can be achieved by anti-inflammatory T2 cytokines such as interleukin (IL)-4 administered by gene therapy. In this study we investigated the efficiency of adeno-associated viruses (AAV) vectors in collagen-induced arthritis (CIA). After injection of AAV-LacZ in the tarsus area of mice, the expression of the transgene was localized in the deep muscles cells near the bone. LacZ expression was found in liver, heart and lung after i.m. injection of AAV-LacZ, showing a spread of the vector over the body. Anti-AAV neutralizing antibodies were detected in the serum after i.m. injection of AAV-LacZ, but they did not alter the transgene expression after re-administration of AAV-LacZ. Long-term IL-4 expression persisted 129 days after intra-muscular injection of 3.7 x 10(10) or 11.2 x 10(10) AAV-IL-4 p.p. (average 7.7 or 17.5 pg IL-4/mg proteins, respectively). More importantly, the treatment of CIA with AAV-IL-4 vector in mice produced a therapeutic benefit, since we show a diminished prevalence of the disease, a significant reduction in paw swelling, attenuated histological synovitis and a 10 days delayed onset of arthritis. This is the first evidence that AAV vector-mediated gene therapy using a T2 cytokine is efficient in an animal model of rheumatoid arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.